The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

被引:0
|
作者
Zamani, Farhad [1 ]
Ajdarkosh, Hossein [1 ]
Safarnezhad-Tameshkel, Fahimeh [1 ]
Azarkeivan, Azita [2 ]
Keyvani, Hossein [1 ]
Naserifar, Farshad [1 ]
Vafaeimanesh, Jamshid [1 ,3 ]
机构
[1] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran
[2] Blood Transfus Res Ctr, High Inst Res & Educ Transfus Med, Thalassemia Clin, Pediat Hematol Oncol, Tehran, Iran
[3] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran
关键词
Anaemia; daclatasvir; hepatitis C virus; sofosbuvir; thalassaemia major; ADVANCED LIVER-DISEASE; HCV GENOTYPE 1; VIRUS-INFECTION; PHASE-III; RIBAVIRIN; LEDIPASVIR; COMBINATION; PREVALENCE; CIRRHOSIS; NAIVE;
D O I
10.4103/ijmm.IJMM_18_90
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Context: Patients with thalassaemia arc at risk of infections such as hepatitis C virus (HCV) due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients who had developed HCV infection is a controversial issue. Aims: Although the effectiveness of direct-acting anti virals on HCV infection has been confirmed, their side-effects as well as effects on haematological factors due to the resultant need for blood transfusion remain to be further understood. Materials and Methods: In this study, 61 patients with major beta thalassaemia and HCV infection, and who had a history of interferon treatment failure were examined. The patients underwent a 24-week treatment with sofosbuvir (SOF) and daclatasvir (DAC). Sustained virological response 12 was used to assess response to treatment. At the end of the study, the need for blood transfusion and serum terrain was evaluated. Results: About 98.4% of the patients responded to the treatment, and only one patient with genotype 1b did not respond positively. No significant complications necessitating treatment cessation were observed, and all the patients tolerated the treatment well. The level of liver enzymes showed a significant reduction 12 weeks after the treatment. The need for blood transfusions in patients before treatment was averagely 1.595 +/- 0.65 bag per month, in which 1.593 +/- 0.64 bags were received after treatment (P = 0.9). This regimen did not affect the amount of anaemia in patients and did not differentiate the need for blood transfusions. The rate of haemoglobin before treatment was 9.5 +/- 1.42 g/dl, which reached 9.6 +/- 1.6 g/dl after treatment (P = 0.54). Ferritin levels decreased significantly (from 1948.08 +/- 1539.54 to 1315.73 +/- 1207.67 ng/ml) (P = 0.001) in the patients after the treatment. Conclusion: Combination of SOF and DAC is an effective and tolerable treatment regimen without affect on the amount of anaemia in patients and did not differentiate the need for blood transfusions.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [1] Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
    El Kassas, Mohamed
    Abdeen, Nermeen
    Omran, Dalia
    Alboraie, Mohamed
    Salaheldin, Mohamed
    Eltabbakh, Mohamed
    Farghaly, Rasha
    Emadeldeen, Mohammed
    Afify, Shimaa
    Sweedy, Ahmad
    Ghalwash, Ahmed
    Abbass, Amr
    Ezzat, Sameera
    Tahoon, Marwa
    ELshazly, Helmy M.
    Hamdy, Hassan
    Omar, Heba
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E877 - E882
  • [2] Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis
    Ismail, Waleed A.
    Yousef, Ayman E.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (08) : 1025 - 1029
  • [3] Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C
    Rivero-Juarez, Antonio
    Brieva, Teresa
    Frias, Mario
    Rivero, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (09) : 901 - 910
  • [4] Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Loomis, Timothy P.
    Mole, Larry A.
    Backus, Lisa I.
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 15 - 23
  • [5] Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4
    Abdel Ghaffar, Tawhida Y.
    El Naghi, Suzan
    Abdel Gawad, Manal
    Helmy, Sarah
    Abdel Ghaffar, Aisha
    Yousef, Medhat
    Moafy, Mohamad
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (02) : 263 - 270
  • [6] Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients
    Mohamed, Mohamed S.
    Hanafy, Amr S.
    Bassiony, Mohamed A. A.
    Hussein, Samia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (12) : 1368 - 1372
  • [7] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
  • [8] Efficacy of Combination Therapy Sofosbuvir, Daclatasvir and Ribavirin in Patients of Hepatitis C
    Quddus, Muhammad Abdul
    Zaib, Jahangir
    Munawar, Rukhsana
    Siddiq, Shazia
    Tahir, Rabia
    Kiani, Rizwan Saeed
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2823 - 2825
  • [9] Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi
    Butt, Nazish
    Anoshia
    Khan, Muhammad Ali
    Akbar, Ali
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2021, 37 (07) : 2014 - 2019
  • [10] Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
    Phil McEwan
    Samantha Webster
    Thomas Ward
    Michael Brenner
    Anupama Kalsekar
    Yong Yuan
    Cost Effectiveness and Resource Allocation, 15